B&L merger approved

Article

Bausch & Lomb's shareholders have voted to approve a merger with Warburg Pincus.

Bausch & Lomb's shareholders have voted to approve a merger with Warburg Pincus.

In accordance with the terms of the merger, each outstanding share of common and Class B stock will be cancelled and converted into the right to receive $65 in cash, without interest, less any applicable withholding taxes.

The merger is expected to close early in the fourth quarter of this year.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.